• Gastrotech Pharma A/S, of Copenhagen, Denmark, completed a $6 million Series D round to support its Phase IIb development program for GTP-010 in pain in irritable bowel disease. Funds also will be used to advance Phase II work on GTP-300, a ghrelin peptide, in cancer-associated cachexia and anorexia. CAT Invest I A/S, of Copenhagen, led the round, with participation from existing investors, including Nordic Biotech, BML Healthcare I LP and 123MultiNova Europe.

• Genta Inc., of Berkeley Heights, N.J., entered agreements with institutional investors to sell 6 million shares of common stock for gross proceeds of about $3.1 million. The financing, to close around Feb. 13, is expected to be used to secure a revenue stream outside the U.S. and to diversify and develop the company's product portfolio and for general corporate purposes. Genta had cash, equivalents and marketable securities totaling $15.5 million as of Sept. 30. Rodman & Renshaw LLC served as the placement agent. Shares of Genta (NASDAQ:GNTA) fell 18 cents Monday to close at 52 cents.

• Light Sciences Oncology Inc., of Bellevue, Wash., withdrew its filing for a proposed initial public offering, citing unfavorable market conditions. The company filed for the IPO in April 2006, hoping to raise as much as $86 million to fund ongoing work with Litx, a drug/device combination product to treat cancer. (See BioWorld Today, April, 26, 2006.)